Amarin Corp Plcuk (AMRN) Net Equity Issued and Repurchased (2011 - 2019)
Amarin Corp Plc\Uk (AMRN) posted quarterly Net Equity Issued and Repurchased of -$837000.0 for Q4 2019, down 100.43% year-over-year from $194.8 million in Q4 2018, and down 100.19% quarter-over-quarter from $440.1 million in Q3 2019.
Amarin Corp Plcuk (AMRN) Net Equity Issued and Repurchased (2011 - 2019) Analysis & Trends
Amarin Corp Plc\Uk (AMRN) has reported Net Equity Issued and Repurchased for 4 consecutive years, with -$837000.0 the latest figure, recorded in Q4 2019.
- In Q4 2019, Net Equity Issued and Repurchased fell 100.43% year-over-year to -$837000.0; the TTM figure through Sep 2022 stood at -$837000.0 (down 100.19% YoY), while the FY2019 annual figure was $440.1 million, up 66.18% from the prior year.
- Net Equity Issued and Repurchased eased to -$837000.0 in Q4 2019 per AMRN's latest filing, from $440.1 million in the prior quarter.
- Across five years, Net Equity Issued and Repurchased topped out at $440.1 million in Q3 2019 and bottomed at -$837000.0 in Q4 2019.
- Historically, Net Equity Issued and Repurchased has averaged $100.6 million across 3 years, with a median of $423000.0 in 2018.
- On a YoY basis, Net Equity Issued and Repurchased climbed as much as 104144.44% in 2019 and fell as far as 100.43% in 2019.
- Amarin Corp Plc\Uk's Net Equity Issued and Repurchased stood at -$1000.0 in 2016, then surged by 19483400.0% to $194.8 million in 2018, then slumped by 100.43% to -$837000.0 in 2019.
- Business Quant data shows AMRN's Net Equity Issued and Repurchased at -$837000.0 in Q4 2019, $440.1 million in Q3 2019, and $194.8 million in Q4 2018.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | - |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | - |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | - |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | - |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 9.00 Mn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | - |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | - |
| 10 | Amarin Corp Plcuk | 5.86 Bn | 5.54 Bn | 14.99 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2019 | -837,000.00 |
| Dec 31, 2019 | -837,000.00 |
| Sep 30, 2019 | 440.11 Mn |
| Sep 30, 2019 | 440.11 Mn |
| Dec 31, 2018 | 194.83 Mn |
| Dec 31, 2018 | 194.83 Mn |
| Sep 30, 2018 | -423,000.00 |
| Sep 30, 2018 | -423,000.00 |
| Jun 30, 2018 | 423,000.00 |
| Jun 30, 2018 | 423,000.00 |
| Mar 31, 2018 | 70.01 Mn |
| Mar 31, 2018 | 70.01 Mn |
| Dec 31, 2016 | -1,000.00 |
| Dec 31, 2016 | -1,000.00 |
| Jun 30, 2011 | -17,000.00 |
| Jun 30, 2011 | -17,000.00 |
| Mar 31, 2011 | 98.67 Mn |
| Mar 31, 2011 | 98.67 Mn |